Form 4: Myriad Genetics Inc. Executive Kevin Richard Haas Reports Stock Transaction
SEC Form 4 Filing
Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports the withholding of 1,016 common stock shares to cover tax obligations related to vesting restricted stock units on February 25, 2025.
Summary
- On February 25, 2025, Kevin Richard Haas, Chief Technology Officer of Myriad Genetics Inc., had 1,016 shares of common stock withheld by the company.
- This withholding was to satisfy tax obligations related to the vesting of restricted stock units.
- The shares were withheld at a price of $11.74 per share.
- Following the transaction, Haas directly owns 128,566 shares of Myriad Genetics Inc. common stock.
Sentiment
Score: 5
Explanation: This is a neutral event related to standard executive compensation practices and tax obligations. It doesn't indicate positive or negative sentiment towards the company's performance.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations. It doesn't necessarily reflect a strategic shift or material event for Myriad Genetics within the broader biotechnology or genetic testing industry.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of stock transaction (tax withholding). |
| 02/26/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.